Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by ICA Group Wealth Management LLC

ICA Group Wealth Management LLC cut its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 82.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51 shares of the biopharmaceutical company’s stock after selling 244 shares during the period. ICA Group Wealth Management LLC’s holdings in Regeneron Pharmaceuticals were worth $54,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Brown Lisle Cummings Inc. raised its stake in Regeneron Pharmaceuticals by 18.2% in the second quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 10 shares in the last quarter. Sachetta LLC raised its stake in Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 10 shares in the last quarter. Team Hewins LLC raised its stake in Regeneron Pharmaceuticals by 2.5% in the first quarter. Team Hewins LLC now owns 451 shares of the biopharmaceutical company’s stock valued at $434,000 after buying an additional 11 shares in the last quarter. Angeles Wealth Management LLC raised its stake in Regeneron Pharmaceuticals by 3.5% in the first quarter. Angeles Wealth Management LLC now owns 325 shares of the biopharmaceutical company’s stock valued at $313,000 after buying an additional 11 shares in the last quarter. Finally, TrinityPoint Wealth LLC grew its holdings in shares of Regeneron Pharmaceuticals by 4.8% during the fourth quarter. TrinityPoint Wealth LLC now owns 262 shares of the biopharmaceutical company’s stock worth $230,000 after purchasing an additional 12 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $1,153.35 on Monday. The firm has a 50 day moving average of $1,124.22 and a 200-day moving average of $1,026.46. Regeneron Pharmaceuticals, Inc. has a 12-month low of $769.19 and a 12-month high of $1,211.20. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. The company has a market cap of $127.08 billion, a price-to-earnings ratio of 34.07, a PEG ratio of 3.97 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The company had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. During the same period last year, the firm earned $8.79 EPS. The company’s revenue for the quarter was up 12.3% on a year-over-year basis. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Barclays raised their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Argus raised their price objective on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a report on Tuesday, June 25th. Truist Financial reaffirmed a “buy” rating and set a $1,200.00 price objective (up previously from $1,135.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 2nd. Guggenheim raised their price objective on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Finally, Morgan Stanley dropped their price objective on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,109.70.

Insider Activity

In other news, EVP Marion Mccourt sold 1,137 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the completion of the sale, the executive vice president now directly owns 12,931 shares in the company, valued at approximately $13,540,179.41. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, EVP Joseph J. Larosa sold 1,866 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $1,088.95, for a total transaction of $2,031,980.70. Following the completion of the transaction, the executive vice president now directly owns 37,937 shares in the company, valued at approximately $41,311,496.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Marion Mccourt sold 1,137 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the transaction, the executive vice president now owns 12,931 shares of the company’s stock, valued at $13,540,179.41. The disclosure for this sale can be found here. In the last three months, insiders sold 10,026 shares of company stock worth $11,498,705. Company insiders own 7.48% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.